Drug Patents owned by Noven

1. List of Minivelle drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9724310 NOVEN Transdermal estrogen device and delivery
Jul, 2028

(5 years from now)

US8231906 NOVEN Transdermal estrogen device and delivery
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730900 NOVEN Transdermal estrogen device and delivery
Jul, 2028

(5 years from now)

US9833419 NOVEN Transdermal estrogen device and delivery
Jul, 2028

(5 years from now)

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 29 October, 2012

Treatment: A method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent no. 9730900

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of MINIVELLE before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in